Last reviewed: June 8, 2026

Last updated: June 8, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The question "Is Mounjaro a GLP-1?" has become increasingly common as tirzepatide gains popularity for weight management. While Mounjaro activates the GLP-1 receptor, it is technically classified as a dual GIP/GLP-1 receptor agonist, not a pure GLP-1 medication. This distinction carries real clinical significance for treatment outcomes.

Understanding the GLP-1 receptor agonist category

GLP-1 receptor agonists are medications designed to mimic glucagon-like peptide-1, a natural hormone that regulates blood sugar and appetite. When GLP-1 agonists bind to their receptor, they slow stomach emptying, increase feelings of fullness, and reduce hunger signals in the brain. Semaglutide (marketed as Ozempic and Wegovy) is the most well-known example of a traditional GLP-1 agonist that activates only the GLP-1 pathway.

The GLP-1 class has demonstrated consistent effectiveness across multiple large clinical trials, with weight loss typically ranging from 15 to 22 percent of body weight depending on dose and individual response. These medications have become standard treatment options for type 2 diabetes and chronic weight management. However, the emergence of dual-action agents has expanded the toolkit available to patients seeking personalized hormone-based therapy.

How tirzepatide differs from traditional GLP-1 medications

Tirzepatide activates two distinct hormone receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). This dual mechanism means tirzepatide engages both appetite-suppression pathways and metabolic pathways simultaneously, potentially creating a stronger overall effect than single-pathway activation. Clinical trials show that tirzepatide users experienced weight loss of 20 to 22 percent at the highest doses, compared to approximately 15 to 18 percent with semaglutide alone.

The GIP receptor pathway itself has been studied since the 1970s but wasn't effectively targeted for weight loss until tirzepatide was developed. GIP contributes to glucose control and may also influence satiety and energy expenditure independently. By simultaneously targeting both GLP-1 and GIP pathways, tirzepatide creates what researchers call a synergistic effect, where the combined action produces greater results than either pathway alone.

Why genetic variation affects your response to tirzepatide

Not every person responds identically to tirzepatide or GLP-1 agonists, and genetic variation plays a measurable role in this individual differences. Key genetic variants in the GLP1R gene (such as rs6923761) and the GIPR gene influence how effectively your cells respond to these medications. PlexusDx's Precision Peptide Genetic Test maps 14 metabolic pathways, 49 peptides, and 150+ genetic insights to identify which peptide-based therapies align with your unique biology.

Understanding your genetic predispositions helps explain why some patients achieve dramatic weight loss while others experience more modest results with the same medication. The FTO gene variant (rs9939609) and MC4R variant (rs17782313) also correlate with baseline obesity risk and medication responsiveness. By identifying your specific genetic profile, PlexusDx can recommend whether tirzepatide, semaglutide, or a combination approach is most likely to match your metabolism.

PlexusDx compounded tirzepatide as a personalized alternative

PlexusDx offers compounded tirzepatide injection formulations prepared by licensed 503A compounding pharmacies, delivering the same active ingredient as brand-name Mounjaro but with flexible dosing and personalized adjustment options. Compounded tirzepatide injection begins at $249 per month and maintains a flat price regardless of dose escalation—your dose may need to go up, your price won't. This pricing structure removes financial barriers to finding your optimal therapeutic dose.

PlexusDx serves all 50 states with no insurance requirement, no membership fees, and HSA/FSA eligibility for all peptide medications. After your first month of treatment, adding the Precision Peptide Genetic Test for $99 provides a detailed genetic roadmap showing which receptor pathways your body activates most efficiently. Oral tirzepatide formulations are also available for patients who prefer non-injection therapy, starting at $279 per month.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Mounjaro exactly the same as a GLP-1 medication?

Mounjaro (tirzepatide) activates the GLP-1 receptor but is classified as a GIP/GLP-1 dual receptor agonist because it also targets the GIP pathway. This dual action distinguishes it from single-action GLP-1 agonists like semaglutide and may explain why some patients achieve stronger weight loss outcomes with tirzepatide.

What clinical evidence supports tirzepatide's effectiveness?

In the SURMOUNT clinical trials, tirzepatide demonstrated weight loss of 20 to 22 percent at maximum doses, compared to approximately 15 to 18 percent with semaglutide in comparable studies. The dual GIP/GLP-1 mechanism appears to produce greater metabolic effects than single-pathway activation alone.

How much does PlexusDx compounded tirzepatide cost?

PlexusDx compounded tirzepatide injection starts at $249 per month with a flat price structure across all dose levels. No insurance is required, and the medication is HSA/FSA eligible. Add the Precision Peptide Genetic Test for $99 after your first month to identify which peptide pathways your genetics favor most.

Are there side effects specific to the GIP/GLP-1 dual mechanism?

Tirzepatide and traditional GLP-1 agonists share common side effects like nausea, constipation, and reduced appetite, which typically diminish over weeks as the body adjusts. Serious adverse events remain rare. Some patients report slightly stronger appetite suppression with tirzepatide due to dual pathway activation.

How does the Precision Peptide Genetic Test help me choose between tirzepatide and semaglutide?

PlexusDx's Precision Peptide Genetic Test analyzes variants in GLP1R, GIPR, FTO, MC4R, and 10 additional pathways to show which hormone receptors your genetics prime for optimal activation. This data helps your provider recommend whether tirzepatide's dual action or semaglutide's single-pathway focus better matches your metabolic profile.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake →

~60 seconds · $0 charged until your provider approves